Inhibition of NF-κB might be insufficient to improve outcomes in addition to R-CHOP in diffuse large B-cell lymphoma, or bortezomib at the doses given might not have been sufficient to inhibit NF-κB adequately for outcomes to improve. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.